231 related articles for article (PubMed ID: 19631529)
21. Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.
Watson RJ; Allen DR; Birch HL; Chapman GA; Galvin FC; Jopling LA; Knight RL; Meier D; Oliver K; Meissner JW; Owen DA; Thomas EJ; Tremayne N; Williams SC
Bioorg Med Chem Lett; 2008 Jan; 18(1):147-51. PubMed ID: 18032038
[TBL] [Abstract][Full Text] [Related]
22. III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold.
Kim SH; Anilkumar GN; Zawacki LG; Zeng Q; Yang DY; Shao Y; Dong G; Xu X; Yu W; Jiang Y; Jenh CH; Hall JW; Carroll CD; Hobbs DW; Baldwin JJ; McGuinness BF; Rosenblum SB; Kozlowski JA; Shankar BB; Shih NY
Bioorg Med Chem Lett; 2011 Dec; 21(23):6982-6. PubMed ID: 22018463
[TBL] [Abstract][Full Text] [Related]
23. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.
Kinzel O; Alfieri A; Altamura S; Brunetti M; Bufali S; Colaceci F; Ferrigno F; Filocamo G; Fonsi M; Gallinari P; Malancona S; Hernando JI; Monteagudo E; Orsale MV; Palumbi MC; Pucci V; Rowley M; Sasso R; Scarpelli R; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2011 Aug; 21(15):4429-35. PubMed ID: 21737263
[TBL] [Abstract][Full Text] [Related]
24. Palladium catalyzed one-pot sequential Suzuki cross-coupling-direct C-H functionalization of imidazo[1,2-a]pyrazines.
Gembus V; Bonfanti JF; Querolle O; Jubault P; Levacher V; Hoarau C
Org Lett; 2012 Dec; 14(23):6012-5. PubMed ID: 23151283
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a novel series of CXCR3 antagonists.
Crosignani S; Missotten M; Cleva C; Dondi R; Ratinaud Y; Humbert Y; Mandal AB; Bombrun A; Power C; Chollet A; Proudfoot A
Bioorg Med Chem Lett; 2010 Jun; 20(12):3614-7. PubMed ID: 20483605
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.
Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
Bioorg Med Chem Lett; 2013 Jul; 23(13):3857-63. PubMed ID: 23719231
[TBL] [Abstract][Full Text] [Related]
27. Access to novel imidazo[1,5-a]pyrazine scaffolds by the combined use of a three-component reaction and a base-assisted intramolecular cyclization.
Attanasi OA; Favi G; Giorgi G; Majer R; Perrulli FR; Santeusanio S
Org Biomol Chem; 2014 Jul; 12(26):4610-9. PubMed ID: 24848196
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.
Bongartz JP; Buntinx M; Coesemans E; Hermans B; Lommen GV; Wauwe JV
Bioorg Med Chem Lett; 2008 Nov; 18(21):5819-23. PubMed ID: 18922694
[TBL] [Abstract][Full Text] [Related]
29. Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A
Poli D; Falsini M; Varano F; Betti M; Varani K; Vincenzi F; Pugliese AM; Pedata F; Dal Ben D; Thomas A; Palchetti I; Bettazzi F; Catarzi D; Colotta V
Eur J Med Chem; 2017 Jan; 125():611-628. PubMed ID: 27721147
[TBL] [Abstract][Full Text] [Related]
30. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.
Tardy S; Orsato A; Mologni L; Bisson WH; Donadoni C; Gambacorti-Passerini C; Scapozza L; Gueyrard D; Goekjian PG
Bioorg Med Chem; 2014 Feb; 22(4):1303-12. PubMed ID: 24468632
[TBL] [Abstract][Full Text] [Related]
32. Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl)quinolines.
Knight RL; Allen DR; Birch HL; Chapman GA; Galvin FC; Jopling LA; Lock CJ; Meissner JW; Owen DA; Raphy G; Watson RJ; Williams SC
Bioorg Med Chem Lett; 2008 Jan; 18(2):629-33. PubMed ID: 18068363
[TBL] [Abstract][Full Text] [Related]
33. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436
[TBL] [Abstract][Full Text] [Related]
34. Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.
Wang Y; Busch-Petersen J; Wang F; Kiesow TJ; Graybill TL; Jin J; Yang Z; Foley JJ; Hunsberger GE; Schmidt DB; Sarau HM; Capper-Spudich EA; Wu Z; Fisher LS; McQueney MS; Rivero RA; Widdowson KL
Bioorg Med Chem Lett; 2009 Jan; 19(1):114-8. PubMed ID: 19014886
[TBL] [Abstract][Full Text] [Related]
35. Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
Martínez González S; Rodríguez-Arístegui S; Hernández AI; Varela C; González Cantalapiedra E; Álvarez RM; Rodríguez Hergueta A; Bischoff JR; Albarrán MI; Cebriá A; Cendón E; Cebrián D; Alfonso P; Pastor J
Bioorg Med Chem Lett; 2017 Jun; 27(11):2536-2543. PubMed ID: 28404374
[TBL] [Abstract][Full Text] [Related]
36. Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3.
Hayes ME; Breinlinger EC; Wallace GA; Grongsaard P; Miao W; McPherson MJ; Stoffel RH; Green DW; Roth GP
Bioorg Med Chem Lett; 2008 Apr; 18(7):2414-9. PubMed ID: 18337097
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of imidazo[1,2-a]pyridines: "water-mediated" hydroamination and silver-catalyzed aminooxygenation.
Chandra Mohan D; Nageswara Rao S; Adimurthy S
J Org Chem; 2013 Feb; 78(3):1266-72. PubMed ID: 23289894
[TBL] [Abstract][Full Text] [Related]
38. 2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion.
Sayer JR; Walldén K; Pesnot T; Campbell F; Gane PJ; Simone M; Koss H; Buelens F; Boyle TP; Selwood DL; Waksman G; Tabor AB
Bioorg Med Chem; 2014 Nov; 22(22):6459-70. PubMed ID: 25438770
[TBL] [Abstract][Full Text] [Related]
39. [Hexahydroimidazo[1,5-a]pyrazine. I. Synthesis of 7-methyl-1,5,6,7,8a-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one and derivatives].
Omodei-Salé A; Toja E
Farmaco Sci; 1975 Aug; 30(08):650-65. PubMed ID: 1149876
[TBL] [Abstract][Full Text] [Related]
40. Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.
Chen P; Doweyko AM; Norris D; Gu HH; Spergel SH; Das J; Moquin RV; Lin J; Wityak J; Iwanowicz EJ; McIntyre KW; Shuster DJ; Behnia K; Chong S; de Fex H; Pang S; Pitt S; Shen DR; Thrall S; Stanley P; Kocy OR; Witmer MR; Kanner SB; Schieven GL; Barrish JC
J Med Chem; 2004 Aug; 47(18):4517-29. PubMed ID: 15317463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
